Abstract: The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.
Type:
Application
Filed:
July 8, 2010
Publication date:
January 12, 2012
Applicants:
AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO, HUMANITAS MIRASOLE S.p.A.
Inventors:
Barbara BOTTAZZI, Alberto Mantovani, Tiziano Barbui, Alessandro Rambaldi